Compare Pfizer with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs PROCTER & GAMBLE HEALTH - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER PROCTER & GAMBLE HEALTH PFIZER/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 32.7 52.7 62.1% View Chart
P/BV x 5.5 4.8 115.2% View Chart
Dividend Yield % 0.6 10.0 6.2%  

Financials

 PFIZER   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    PFIZER
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
PFIZER/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs2,3653,549 66.6%   
Low Rs1,6251,301 124.9%   
Sales per share (Unadj.) Rs430.3511.4 84.1%  
Earnings per share (Unadj.) Rs78.761.3 128.4%  
Cash flow per share (Unadj.) Rs93.274.0 125.9%  
Dividends per share (Unadj.) Rs20.00440.00 4.5%  
Dividend yield (eoy) %1.018.1 5.5%  
Book value per share (Unadj.) Rs586.5927.8 63.2%  
Shares outstanding (eoy) m45.7516.60 275.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.64.7 97.8%   
Avg P/E ratio x25.339.6 64.1%  
P/CF ratio (eoy) x21.432.8 65.3%  
Price / Book Value ratio x3.42.6 130.1%  
Dividend payout %25.4717.9 3.5%   
Avg Mkt Cap Rs m91,27140,257 226.7%   
No. of employees `0002.61.1 231.9%   
Total wages/salary Rs m3,1431,313 239.4%   
Avg. sales/employee Rs Th7,484.87,486.7 100.0%   
Avg. wages/employee Rs Th1,195.01,157.6 103.2%   
Avg. net profit/employee Rs Th1,369.1897.2 152.6%   
INCOME DATA
Net Sales Rs m19,6858,490 231.9%  
Other income Rs m1,143244 468.6%   
Total revenues Rs m20,8288,734 238.5%   
Gross profit Rs m5,0031,482 337.7%  
Depreciation Rs m663211 313.7%   
Interest Rs m40-   
Profit before tax Rs m5,4791,514 361.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m1,878563 333.9%   
Profit after tax Rs m3,6011,017 353.9%  
Gross profit margin %25.417.5 145.6%  
Effective tax rate %34.337.1 92.3%   
Net profit margin %18.312.0 152.6%  
BALANCE SHEET DATA
Current assets Rs m24,16715,343 157.5%   
Current liabilities Rs m9,5441,960 486.9%   
Net working cap to sales %74.3157.6 47.1%  
Current ratio x2.57.8 32.3%  
Inventory Days Days5549 113.0%  
Debtors Days Days2928 100.9%  
Net fixed assets Rs m9,5141,209 786.7%   
Share capital Rs m458166 275.6%   
"Free" reserves Rs m26,37515,235 173.1%   
Net worth Rs m26,83215,401 174.2%   
Long term debt Rs m250-   
Total assets Rs m36,90017,595 209.7%  
Interest coverage x1,305.5NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 110.6%   
Return on assets %9.85.8 169.0%  
Return on equity %13.46.6 203.1%  
Return on capital %20.410.3 199.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m221,636 1.4%   
Fx outflow Rs m1,4894,368 34.1%   
Net fx Rs m-1,466-2,732 53.7%   
CASH FLOW
From Operations Rs m3,318-1,304 -254.5%  
From Investments Rs m-2,38312,697 -18.8%  
From Financial Activity Rs m-1,104-301 367.2%  
Net Cashflow Rs m-16911,093 -1.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 51.8 123.4%  
Indian inst/Mut Fund % 7.5 18.2 41.2%  
FIIs % 4.9 1.0 490.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 29.1 81.4%  
Shareholders   85,207 28,591 298.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   SHASUN PHARMA  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  STERLING BIOTECH  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Oct 18, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS